MAPK3 and diabetes mellitus: At doses that have previously been shown to prevent diabetes-induced vascular dysfunction (Benter et al, 2005a), AG1478 administered chronically (Figure 5a) or acutely (Figure 5b), also attenuted the diabetes-induced changes in total and/or phosphorylated EGFR, ROCK and ERK1/2.